A number of previous studies examining the relationship between PA, endocrine symptoms and QOL among women with BC have predominantly examined arthralgias or musculoskeletal concerns that develop as a result of aromatase inhibitor (AI) therapy for HR+ BC. Here, CYP19A1 is linked to breast cancer.